Meeting
2022 ASCO Genitourinary Cancers Symposium
Analysis of the role of PI3K-AKT and DNA damage repair (DDR) genomic biomarkers as predictors of clinical outcomes in non-metastatic castration-resistant prostate cancer (nmCRPC).
Authors
Richard Gagnon
University of Calgary Cumming School of Medicine, Calgary, AB, Canada
Richard Gagnon , Soufiane El Hallani , Richard M. Lee-Ying , Michael Paul Kolinsky , Daniel Joseph Khalaf , Sarah Cook , Catalina Vasquez , Divya Samuel , John D Lewis , Rehan Faridi , Minal Borkar , Daniel Yick Chin Heng , Nimira S. Alimohamed , Joseph D. Ruether , Geoffrey Gotto , Adrian S. Fairey , Tarek A. Bismar , Steven Yip
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 175)
DOI
10.1200/JCO.2022.40.6_suppl.175
Abstract #
175
Poster Bd #
J11
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.
First Author: Ecaterina Elena Ileana Dumbrava
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2020 ASCO Virtual Scientific Program
Genomic landscape and immune phenotype of malignant pleural mesothelioma.
First Author: Meera Patel
Poster
2020 Genitourinary Cancers Symposium
TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA).
First Author: Johann S. De Bono